|
|
Volumn 1, Issue 2, 2006, Pages 133-140
|
|
Management of cardiovascular risk in patients with type 2 diabetes mellitus as a component of the cardiometabolic syndrome.
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ANTIHYPERTENSIVE AGENT;
ANTIOBESITY AGENT;
ANTITHROMBOCYTIC AGENT;
HIGH DENSITY LIPOPROTEIN CHOLESTEROL;
HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;
TRIACYLGLYCEROL;
BLOOD;
BLOOD PRESSURE;
CARDIOVASCULAR DISEASE;
DRUG COMBINATION;
DRUG EFFECT;
DYSLIPIDEMIA;
HUMAN;
HYPERTENSION;
METABOLIC SYNDROME X;
NON INSULIN DEPENDENT DIABETES MELLITUS;
OBESITY;
PATHOPHYSIOLOGY;
PRACTICE GUIDELINE;
REVIEW;
RISK FACTOR;
TREATMENT OUTCOME;
ANTI-OBESITY AGENTS;
ANTIHYPERTENSIVE AGENTS;
BLOOD PRESSURE;
CARDIOVASCULAR DISEASES;
CHOLESTEROL, HDL;
DIABETES MELLITUS, TYPE 2;
DRUG THERAPY, COMBINATION;
DYSLIPIDEMIAS;
HUMANS;
HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS;
HYPERTENSION;
METABOLIC SYNDROME X;
OBESITY;
PLATELET AGGREGATION INHIBITORS;
PRACTICE GUIDELINES;
RISK FACTORS;
TREATMENT OUTCOME;
TRIGLYCERIDES;
|
|
EID: 34548057004
PISSN: 15594564
EISSN: None
Source Type: Journal
DOI: 10.1111/j.1559-4564.2006.05487.x Document Type: Review |
|
Times cited : (9)
|
|
References (51)
|
